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1000 1 #24516 23 #24  0/110 ± 0/190  0/40 ± 0/77  0/92 ± 0/199  
2000 1 #24516 23 #24  0/62 ± 0/159  0/28 ± 5/49  0/130 ± 0/173  
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./  ! ,& 7 3 ./  500 1 #24516 23 #24   0/49 ± 0/223  0/40 ± 7/85  0/63 ± 0/180  
86 91:1  0/88 ± 7/204  0/54 ± 6/80  0/76 ± 8/180  
ALP: Alkaline phosphatise; SGPT: Serum glutamic-pyruvic transaminase; SGOT: Serum glutamic oxaloacetic transaminase 
  
} J5E G,~*  <%U  F 	% 	6B   	: ,  
 +6
Alkaline phosphatise )ALP (SGPT   
)Serum glutamic-pyruvic transaminase  (SGOT   
)Serum glutamic oxaloacetic transaminase, = (  ?% 
) 	%05/0 > P ,` .(  $%	2 rWj   , B 
 |DSGPT SGOT  ALP  ;	) 2 . 	U  
 1) *%#   ,!-" & 2 3'4&5  %    
$E } 	6B ^J*\ E ,    	% ?%  9^J*\
, = 25 U G*   :	% ) 	: ,  
)05/0 > P.(  
  
&'  
 $5JD = 70    K7   	%	: -*  ,
   Z* $%	2   =,B .	2E, ,
 B   
 $5JD =100 W  3,WB , 3, =,?  4000 W  3,
 3,WB , . $ F  Z* , F =2T  
/C  $%	2   B  500  W 3,WB , 3, ,

<%U |D $5JD =  .	2E,  +: 	6B ALP SGPT 
 SGOT  ,\ $WA	 = 1 .	:  = 	6B 
, 25 U G* 	: ,   Z*   ?%  
<%U  Z [<E  	% .:	% ) 	6B   
$5JD   4* 	: 3I% Nazrul-Hakim  $B 9 
W\ ,` , p2 $  	h\K  	: 	) $%   $%	2 B 
  ,30 K 	: 3I% ,% ,ZH K  -* , $ $ 
 < $ /C   Z*  	%	:0 500  1000 W  , 3,
 3,WB F* GH $  % +A ^  O\ .	2E, ,

K /C  G	 $ 72  O\  	% $E, ,p% Z* C  
<%U .	%	: $?B U  +: 	6B Alanine aminotransferase 
)ALT  (Gamma-glutamyl transferase )GGT	% (  ,
 ,\ =  3	B } $B  ?% % .	: ,   
	22B E   25 U G* 	: ,  /C 
) :	%16.(  
 $5JD   4* 	: 3I%Tennekoon  <E 9 [ 
 	? +
  |D GGT  ALP    O\ E  BA 
/C  $%	2 $%   B  %  $B 	: K<  $5JD 
~ ,R]G, ) 18$5JD  .( ^J*\ ,R] ~* 	6B*,  
   	% ?%} ,  3	B    U G* $WA	  
25  , 	: ) :	% . $5JD  4* 	: 3I%
Nazrul-Hakim ^J*\ 9  % 	6B E< ,  $ $B 	:
B 	- <) @ -]< ,>   	?% 	?= ,    
U G* $5JD 25  ):	% )16.(  
$5JD    , 9  	%&\ 4* 	: 3I% 
$%	2 E G,~* +()   E  	5 6{ 2:
 BA K  rWj   .	: 	?  $ b6 
$5JD %  U  	6B  	: I G,~* $B  ?%  ;6% $
$%	2 .,/  O\   ? lE  E 6( B 
	v2 *h =   $5JD = X
   E =  
 ,B7   = 	6B m] ,` ) :25.(  
	2 ?% $5JD = %   F*  $B  =  
$%	2  * B  4000 W 3,WB , 3,   ^J*\ }
 % I F^J ,p%  $%  <%U ,p%  $% 	6B  	%
$5JD 0D    W6
7  A, $ ,I2  =  
 $WB  F^J*\ G,~*   K U .bA $B :
25 , ,     <%   ,  <% (? %   ?%




 	 –  34 
 / 376 ! / " # $%&1395 281 
 	 
        	   
$E  $B 	: 	 G5JD $5JD  ] )  %j ,R9 .(
$%	2 ,`n*  , $5JD %  $% B    , 	2
% ?%  ,j G,` 	6B E  $5JD  :% %  	 
 ,`n*$%	2  , +()   G5JD A,  $WB  	6B E
 $E  ,~ ,> A,   0D $5JD   ,R]   
)48-43 32.(  
$5JD % 061   * ,R] 4000 W  3,WB , 3, 
/C    $%	2  F* GH $ B  6%) G,` 
 	6B  $WB  , % ?%     	   ,B
 G	 %&1 GH $   $WB E  (2*  LC = 	%*
) 	2B I U J5E53-49.(  
 O\  *B GH $   = <I* 	:  *
  G	 $RC  $ b6  , 	Z  	29% I 
 GH $  WB J5E  = G	 %&1   
  .,/ $WB  ;bA I GH   : , g*,
 4* $5)  X: 1 $  = $B ) U  .: XD

   3,  A WC $ =2T  : U :  
)54 30-28 $B  % (  * , tj?  = 
 LC I 	 U ,B $   $  3, 
 , <I* F:<\ 4*  , ]   ,B 2
)58-55 (2?\  =  .( , G5JD :   ,*  
 ]  ,*&  ;	   F* $%    3I% %] 
 $B = 	 $ .,  =2T ., tj?  = 
 W\ 	2%  = <)  , ,> G5JD $6: 	h\
  :%  =  $B , tj? * , 3I% U =J%
 U <) 3	B    * 	:WC GH $ U %  ,*.  
  
()  "*+  
 : $ *--Z* |,1 +H] $J- = 1182   $B 
$) =E  G--Z* %5  U ,B,(: 9:<\ 3WC >?% 
 $B ,E ,  3,Z %5 U  $W =	 . 	: 3I%
 9 $5JD = ,)  %	
 	2: :. 
  
References 
1. Rafieian-Kopaei M. Medicinal plants and the human 
needs. J Herbmed Plarmacol 2012; 1(1): 1–2. 
2. Nasri H, Shirzad H. Toxicity and safety of medicinal 
plants. J Herb Med Plarmacol 2013; 2(2): 21-2. 
3. Ghaderian SB, Beladi-Mousavi SS. The role of 
diabetes mellitus and hypertension in chronic kidney 
disease. J Renal Inj Prev 2014; 3(4): 109-10. 
4. Nazar CMJ. Mechanism of hypertension in diabetic 
nephropathy. J Nephropharmacol 2014; 3(2): 49-55. 
5. Tavafi M. Antioxidants against contrast media 
induced nephrotoxicity. J Renal Inj Prev 2014; 3(2): 
55-6. 
6. Rafieian-Kopaei M, Baradaran A, Merrikhi A, 
Nematbakhsh M, Madihi Y, Nasri H. Efficacy of co-
administration of garlic extract and metformin for 
prevention of gentamicin-renal toxicity in wistar rats: 
A biochemical study. Int J Prev Med 2013; 4(3):  
258-64. 
7. Nasri H, Nematbakhsh M, Ghobadi S, Ansari R, 
Shahinfard N, Rafieian-Kopaei M. Preventive and 
curative effects of ginger extract against 
histopathologic changes of gentamicin-induced 
tubular toxicity in rats. Int J Prev Med 2013; 4(3): 
316-21. 
8. Shahraki MR, Miri Moghadam E, Palan MJ. The 
survey of Teucrium Polium toxicity effect on liver 
and serum lipoproteins in normoglycemic male rat. 
Zahedan J Res Med Sci 2006; 8(3): 227-32.  
[In Persian]. 
9. Mardani S, Nasri H, Hajian S, Ahmadi A, Kazemi R, 
Rafieian-Kopaei M. Impact of Momordica charantia 
extract on kidney function and structure in mice. J 
Nephropathol 2014; 3(1): 35-40. 
10. Basch E, Gabardi S, Ulbricht C. Bitter melon 
(Momordica charantia): A review of efficacy and 
safety. Am J Health Syst Pharm 2003; 60(4): 356-9. 
11. Grover JK, Yadav SP. Pharmacological actions and 
potential uses of Momordica charantia: A review. J 
Ethnopharmacol 2004; 93(1): 123-32. 
12. Jayasooriya AP, Sakono M, Yukizaki C, Kawano M, 
Yamamoto K, Fukuda N. Effects of Momordica 
charantia powder on serum glucose levels and various 
lipid parameters in rats fed with cholesterol-free and 
cholesterol-enriched diets. J Ethnopharmacol 2000; 
72(1-2): 331-6. 
13. Bano F, Akthar N, Naz H. Effect of the aqueous 
extracts of Momordica charantia on body weight of 
rats. J Basic Appl Sci 2011; 7(1): 1-5. 
14. Shibib BA, Khan LA, Rahman R. Hypoglycaemic 
activity of Coccinia indica and Momordica 
charantia in diabetic rats: Depression of the 
hepatic gluconeogenic enzymes glucose-6-
phosphatase and fructose-1,6-bisphosphatase and 
elevation of both liver and red-cell shunt enzyme 
glucose-6-phosphate dehydrogenase. Biochem J 
1993; 292 (Pt 1): 267-70. 
15. Platel K, Shurpalekar KS, Srinivasan K. Influence of 
bitter gourd (Momordica charantia) on growth and 
blood constituents in albino rats. Nahrung 1993; 
37(2): 156-60. 
16. Nazrul-Hakim M, Yaacob A, Adam Y, Zuraini A. 
Preliminary toxicological evaluations of polypeptide-
k isolated from Momordica charantia in laboratory 
rats. International Journal of Biological, 
Biomolecular, Agricultural, Food and 
Biotechnological Engineering 2011; 5(3). 




 	 –  34 
 / 376 ! / "# $%& 1395 282 
 	 
        	   
17. Dixit VP, Khanna P, Bhargava SK. Effects of 
Momordica charantia L. fruit extract on the 
testicular function of dog. Planta Med 1978; 34(3): 
280-6. 
18. Tennekoon KH, Jeevathayaparan S, Angunawala P, 
Karunanayake EH, Jayasinghe KS. Effect of 
Momordica charantia on key hepatic enzymes. J 
Ethnopharmacol 1994; 44(2): 93-7. 
19. Paul A, Raychaudhuri SS. Medicinal uses and 
molecular identification of two Momordica charantia 
varieties–a review. Electronic Journal of Biology 
2010; 6(2): 43-51. 
20. Raman A, Lau C. Anti-diabetic properties and 
phytochemistry of Momordica charantia L. 
(Cucurbitaceae). Phytomedicine 1996; 2(4): 349-62. 
21. Virdi J, Sivakami S, Shahani S, Suthar AC, 
Banavalikar MM, Biyani MK. Antihyperglycemic 
effects of three extracts from Momordica charantia. J 
Ethnopharmacol 2003; 88(1): 107-11. 
22. Fallahzadeh MH, Fallahzadeh MA. On the occasion 
of world kidney disease 2016; renal disease in 
children. Acta Persica Pathophysiol 2016; 1(1): e04. 
23. Pokorny J, Yanishlieva N, Gordon MH. Antioxidants 
in food: practical applications. Boca Raton, FL: CRC 
Press; 2001.p. 50-60. 
24. Amiri M, Motamedi P, Vakili L, Dehghani N, Kiani 
F, Taheri Z, et al. Beyond the liver protective 
efficacy of silymarin; bright renoprotective effect 
on diabetic kidney disease. J Nephropharmacol 
2014; 3(2): 25-6. 
25. Pooladvand V, Taghavi MM, Mahmoodi M, 
Tavakolian V. Histological alterations due to the 
consumption of different doses of Citrullus 
colocynthis fruit in normal and diabetic male rats. J 
Mazandaran Univ Med Sci 2011; 21(82): 63-72.  
[In Persian]. 
26. Bahmani M, Rafieian M, Baradaran A, Rafieian S, 
Rafieian-Kopaei M. Nephrotoxicity and 
hepatotoxicity evaluation of Crocus sativus stigmas 
in neonates of nursing mice. J Nephropathol 2014; 
3(2): 81-5. 
27. Hajibabaei K. The role of antioxidants and pro-
oxidants in the prevention and treatment of cancers. 
Ann Res Antioxid 2016; 1(1): e09. 
28. Dehghan Shahreza F. From oxidative stress to 
endothelial cell dysfunction. J Prev Epidemiol 2016; 
1:e04. 
29. Lala MA, Nazar CMJ, Lala HA, Singh JK. 
Interrelation between blood pressure and diabetes. J 
Renal Endocrinol 2015; 1: e05. 
30. Kafeshani M. Ginger, micro-inflammation and 
kidney disease. J Renal Endocrinol 2015; 1: e04. 
31. Rafieian-Kopaei M, Baradaran A, Rafieian M. Plants 
antioxidants: From laboratory to clinic. J 
Nephropathol 2013; 2(2): 152-3. 
32. Hajivandi A, Amiri M. World Kidney Day 2014: 
Kidney disease and elderly. J Parathyr Dis 2014; 
2(1): 3-4. 
33. Dehghan Shahreza F. Vascular protection by herbal 
antioxidants; recent views and new concepts. J Prev 
Epidemiol 2016; 1: e05. 
34. Baradaran A, Nasri H, Nematbakhsh M, Rafieian-
Kopaei M. Antioxidant activity and preventive effect 
of aqueous leaf extract of Aloe Vera on gentamicin-
induced nephrotoxicity in male Wistar rats. Clin Ter 
2014; 165(1): 7-11. 
35. Nazar CMJ. Significance of diet in chronic kidney 
disease J Nephropharmacol 2013; 2(2): 37-43. 
36. Nasri H, Abedi-Gheshlaghi Z, Rafieian-Kopaei M. 
Curcumin and kidney protection; current findings and 
new concepts. Acta Persica Pathophysiol 2016;  
1(1): e01. 
37. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-
Kopaei M. Impact of oral vitamin D (cholecalciferol) 
replacement therapy on blood pressure in type 2 
diabetes patients; a randomized, double-blind, 
placebo controlled clinical trial. J Nephropathol 2014; 
3(1): 29-33. 
38. Hajivandi A, Amiri M. World diabetes day: Diabetes 
mellitus and nephrology. J Nephropharmacol 2013; 
2(2):31-2. 
39. Nasri H, Yazdani M. The relationship between serum 
LDL-cholesterol, HDL-cholesterol and systolic blood 
pressure in patients with type 2 diabetes. Kardiol Pol 
2006; 64(12): 1364-8. 
40. Tavafi M, Hasanvand A, Ashoory H. Proximal 
convoluted tubule cells in ischemia and post-injury 
regeneration. Acta Persica Pathophysiol 2016;  
1(1): e05. 
41. Benzie IF, Strain JJ. The ferric reducing ability of 
plasma (FRAP) as a measure of "antioxidant power": 
The FRAP assay. Anal Biochem 1996; 239(1): 70-6. 
42. Mirhosseini M, Baradaran A, Rafieian-Kopaei M. 
Anethum graveolens and hyperlipidemia: A 
randomized clinical trial. J Res Med Sci 2014; 19(8): 
758-61. 
43. Khodadadi S. Role of herbal medicine in boosting 
immune system. Immunopathol Persa 2015; 1(1): e01. 
44. Aleebrahim-Dehkordy E, Khodadadi S, 
Mousavipanah Z, Nasri H. Herbal antioxidants and 
kidney. Ann Res Antioxid 2016; 1(1): e10. 
45. Gulleroglu K, Bayrakci U, Tulgar KS, Uslu N, Ok 
AA, Sarialioglu F, et al. Neuroblastoma accompanied 
by hyperaldosteronism. J Renal Inj Prev 2014; 3(3): 
79-82. 
46. Sabitha V, Ramachandran S, Naveen KR, 
Panneerselvam K. Antidiabetic and antihyperlipidemic 
potential of Abelmoschus esculentus (L.) Moench. in 
streptozotocin-induced diabetic rats. J Pharm Bioallied 
Sci 2011; 3(3): 397-402. 
47. Kaushik A, Jijta Ch, Kaushik JJ, Zeray R, Ambesajir 
A, Beyene L. FRAP (Ferric reducing ability of 
plasma) assay and effect of Diplazium esculentum 
(Retz) Sw. (a green vegetable of North India) on 
central nervous system. Indian J Nat Prod Resour 
2012; 3(2): 228-31. 
48. Dehghan Shahreza F. Mechanistic impact of renal 
tubular cell protection by antioxidants. Ann Res 
Antioxid 2016; 1(1): e06. 
49. Baradaran A. Lipoprotein(a), type 2 diabetes and 
nephropathy; the mystery continues. J Nephropathol 
2012; 1(3): 126-9. 
50. Ardalan MR. Noninvasive methods for diagnosis of 
chronic kidney disease related bone diseases; help or 
hindrance? J Parathyr Dis 2015; 3(2): 28-9. 
51. Amiri M, Hosseini SM. Diabetes mellitus type 1; is it 




 	 –  34 
 / 376 ! / " # $%&1395 283 
 	 
        	   
a global challenge? Acta Epidemioendocrinol 2016; 
1(1): e02.  
52. Nasri H, Shirzad H, Baradaran A, Rafieian-Kopaei 
M. Antioxidant plants and diabetes mellitus. J Res 
Med Sci 2015; 20(5): 491-502. 
53. Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative 
stress and hypertension: Possibility of hypertension 
therapy with antioxidants. J Res Med Sci 2014; 19(4): 
358-67. 
54. Momeni A. Cardiovascular complications of renal 
failure in hemodialysis patients. Ann Res Dial 2016; 
1(1): e05. 
55. Hajian S. Positive effect of antioxidants on immune 
system. Immunopathol Persa 2015; 1(1): e02. 
56. Hasanpour Z, Nasri H, Rafieian-Kopaei M, Ahmadi 
A, Baradaran A, Nasri P, et al. Paradoxical effects of 
atorvastatin on renal tubular cells: an experimental 
investigation. Iran J Kidney Dis 2015; 9(3): 215-20. 
57. Nasri H, Rafieian-Kopaei M. Metformin and diabetic 
kidney disease: a mini-review on recent findings. Iran 
J Pediatr 2014; 24(5): 565-8. 
58. Baradaran A, Nasri H, Rafieian-Kopaei M. Protection of 
renal tubular cells by antioxidants: current knowledge 
and new trends. Cell J 2015; 16(4): 568-71. 
  
1- Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 
2- Assistant Professor, Department of Internal Medicine, School of Medicine, Shahrekord University of Medical Sciences, 
Shahrekord, Iran 
3- Professor, Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran 





 	 –  34 
 / 376 ! / " $%& #1395 284 
Journal of Isfahan Medical School Received: 09.12.2015 
 
Vol. 34, No. 376, 4th Week, May 2016 Accepted: 09.03.2016 
 
 
Evaluating the Liver Toxicity of Hydroalcoholic Extract of Momordica Charantia in 
Male Balb/C Mice 
 
Hamid Nasri1, Saeed Mardani2, Mahmoud Rafieian-Kopaei3 
 
Abstract 
Background: Momordica charantia (bitter melon) is known for its hypoglycemic effect and widely used for the 
treatment of diabetes. This study other than evaluating plant antioxidant and its effect on blood antioxidant 
capacity, examined the effects and safety of bitter melon fruit in laboratory mice.  
Methods: 70 male mice (2-3 weeks old, body weight 25-30 g) were randomly divided into 7 groups. The mice 
were acclimatized to laboratory conditions for 7 days and at day 8, they were dosed intraperitoneally (single dose 
groups: 0, 100, 500, 1000, 2000, 4000 mg/kg and the group which was treated for 7 days: 500 mg/kg/day). Mice 
were then observed for 72 hours before they were scarified, immediately livers were taken for histology. Serum 
samples were assayed for liver functions [alkaline phosphatase (ALT), serum glutamic-pyruvic transaminase 
(SGPT) and serum glutamic oxaloacetic transaminase (SGOT)]. Blood and bitter melon antioxidant activity was 
measured. 
Findings: All single dose groups showed normal behavior after the dosing and no statistical changes were 
observed in all liver parameters including for SGOT, SGPT or ALP (P > 0.05). Lab data were shown as follow: 
ALP = 204.7 ± 88.0, SGOT = 180.8 ± 76.0, SGPT = 80.6 ± 54.0. Histological examinations revealed normal 
organ structures. Antioxidant activity of bitter melon was 68% and blood antioxidant activity was 564 µmol/ml. 
Conclusion: Doses up to 4000 mg/kg did not have any effects on the mice liver functions nor its histology. We 
suggest more studies with different doses. 
Keywords: Momordica charantia, Liver, Alkaline phosphatase (ALT), Serum glutamic-pyruvic transaminase 
(SGPT), Serum glutamic oxaloacetic transaminase (SGOT) 
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